BR112013007907A2 - novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase - Google Patents
novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductaseInfo
- Publication number
- BR112013007907A2 BR112013007907A2 BR112013007907A BR112013007907A BR112013007907A2 BR 112013007907 A2 BR112013007907 A2 BR 112013007907A2 BR 112013007907 A BR112013007907 A BR 112013007907A BR 112013007907 A BR112013007907 A BR 112013007907A BR 112013007907 A2 BR112013007907 A2 BR 112013007907A2
- Authority
- BR
- Brazil
- Prior art keywords
- reductase inhibitors
- new substituted
- substituted quinoline
- quinoline compounds
- nitrosoglutathione reductase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39122510P | 2010-10-08 | 2010-10-08 | |
US42380510P | 2010-12-16 | 2010-12-16 | |
PCT/US2011/055200 WO2012048181A1 (en) | 2010-10-08 | 2011-10-07 | Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013007907A2 true BR112013007907A2 (pt) | 2016-06-14 |
Family
ID=45928135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013007907A BR112013007907A2 (pt) | 2010-10-08 | 2011-10-07 | novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase |
Country Status (23)
Country | Link |
---|---|
US (5) | US8921562B2 (pt) |
EP (2) | EP2624695B1 (pt) |
JP (2) | JP5855113B2 (pt) |
KR (1) | KR101886459B1 (pt) |
CN (1) | CN103200820B (pt) |
AU (1) | AU2011311920B2 (pt) |
BR (1) | BR112013007907A2 (pt) |
CA (1) | CA2811791C (pt) |
DK (1) | DK2624695T3 (pt) |
ES (1) | ES2553771T3 (pt) |
HK (2) | HK1187207A1 (pt) |
HR (1) | HRP20151405T1 (pt) |
HU (1) | HUE025653T2 (pt) |
IL (1) | IL223829A (pt) |
IN (1) | IN2013MN00501A (pt) |
PL (1) | PL2624695T3 (pt) |
PT (1) | PT2624695E (pt) |
RS (1) | RS54369B1 (pt) |
RU (1) | RU2599144C2 (pt) |
SI (1) | SI2624695T1 (pt) |
SM (1) | SMT201600021B (pt) |
WO (1) | WO2012048181A1 (pt) |
ZA (1) | ZA201303257B (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8921562B2 (en) | 2010-10-08 | 2014-12-30 | N30 Pharmaceuticals, Inc. | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors |
CN103328430A (zh) | 2010-12-16 | 2013-09-25 | N30医药品公司 | 作为s-亚硝基谷胱甘肽还原酶抑制剂的新型取代的双环芳族化合物 |
WO2012170371A1 (en) * | 2011-06-10 | 2012-12-13 | N30 Pharmaceuticals, Llc | Compounds as s-nitrosoglutathione reductase inhibitors |
WO2016057811A1 (en) * | 2014-10-08 | 2016-04-14 | Nivalis Therapeutics, Inc. | Methods for the treatment of cystic fibrosis |
CN104496998B (zh) * | 2014-12-15 | 2017-07-11 | 陕西嘉禾生物科技股份有限公司 | 一种1′‑苄基‑2′‑酮‑5′,7′,8′‑三氢‑螺‑[1,3‑二氧五环‑2]‑喹啉的制备方法 |
WO2016128905A1 (en) * | 2015-02-10 | 2016-08-18 | Glenmark Pharmaceuticals S.A. | Thienopyrrole compounds as s-nitrosoglutathione reductase inhibitors |
US9840513B2 (en) | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
WO2017044766A1 (en) | 2015-09-10 | 2017-03-16 | Nivalis Therapeutics, Inc. | Solid forms of an s-nitrosoglutathione reductase inhibitor |
WO2017044788A1 (en) * | 2015-09-10 | 2017-03-16 | Nivalis Therapeutics, Inc. | Formulations of an s-nitrosoglutathione reductase inhibitor |
WO2017062611A1 (en) * | 2015-10-07 | 2017-04-13 | Nivalis Therapeutics, Inc. | Methods for the treatment of cystic fibrosis |
CA3001096A1 (en) | 2015-10-09 | 2017-04-13 | Abbvie S.A.R.L. | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use |
BR112018007145A2 (pt) | 2015-10-09 | 2018-11-06 | AbbVie S.à.r.l. | ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso |
BR112018007165A2 (pt) | 2015-10-09 | 2019-01-22 | AbbVie S.à.r.l. | novos compostos para tratamento da fibrose cística |
WO2017151725A1 (en) * | 2016-03-03 | 2017-09-08 | Nivalis Therapeutics, Inc. | Formulations of an s-nitrosoglutathione reductase inhibitor |
CA3016303A1 (en) | 2016-04-26 | 2017-11-02 | Abbvie S.A.R.L. | Modulators of cystic fibrosis transmembrane conductance regulator protein |
US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
US9981910B2 (en) | 2016-10-07 | 2018-05-29 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
US10399940B2 (en) | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
EP3558982A1 (en) | 2016-12-20 | 2019-10-30 | AbbVie S.À.R.L. | Deuterated cftr modulators and methods of use |
TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
WO2019193062A1 (en) | 2018-04-03 | 2019-10-10 | Abbvie S.Á.R.L | Substituted pyrrolidines and their use |
CN108794395B (zh) * | 2018-07-06 | 2021-04-20 | 大连理工大学 | 一种2-喹啉酮类化合物的制备方法 |
US11345691B2 (en) | 2019-06-03 | 2022-05-31 | AbbVie Global Enterprises Ltd. | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
TW202115014A (zh) | 2019-07-12 | 2021-04-16 | 美商奧佛麥德公司 | 用於治療囊腫纖維化之化合物 |
WO2021217028A1 (en) | 2020-04-23 | 2021-10-28 | University Hospitals - Cleveland Medical Center | Compositions and methods for in vivo lung and blood sno repletion |
US20220211692A1 (en) | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
US20220213041A1 (en) | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4431440A (en) | 1981-02-20 | 1984-02-14 | American Cyanamid Company | Method to alter or control the development and/or the life cycle of various plant species |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
DE19517060A1 (de) | 1995-05-10 | 1996-11-14 | Hoechst Ag | 1-Fluorisochinolinderivate und ihre Verwendung in flüssigkristallinen Mischungen |
DE19517038A1 (de) | 1995-05-10 | 1996-11-14 | Hoechst Ag | 1,8-Difluorisochinolinderivate und ihre Verwendung in flüssigkristallinen Mischungen |
JP2000514048A (ja) | 1996-06-20 | 2000-10-24 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 薬理学的活性調製物を提供するための化合物および方法ならびにそれらの使用 |
US6057367A (en) | 1996-08-30 | 2000-05-02 | Duke University | Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses |
WO1998054156A1 (en) | 1997-05-28 | 1998-12-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES |
US6180632B1 (en) | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
CA2318731C (en) | 1998-01-29 | 2012-05-29 | Tularik Inc. | Ppar-gamma modulators |
WO2000058822A1 (en) | 1999-03-30 | 2000-10-05 | British Telecommunications Public Limited Company | Network printing method in apparatus |
JP3649395B2 (ja) | 2000-04-27 | 2005-05-18 | 山之内製薬株式会社 | 縮合ヘテロアリール誘導体 |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
AU2001296502B2 (en) | 2000-10-02 | 2005-06-09 | Molecular Probes, Inc. | Reagents for labeling biomolecules having aldehyde or ketone moieties |
US6359182B1 (en) | 2000-10-26 | 2002-03-19 | Duke University | C-nitroso compounds and use thereof |
US7049308B2 (en) | 2000-10-26 | 2006-05-23 | Duke University | C-nitroso compounds and use thereof |
US7179791B2 (en) | 2001-01-11 | 2007-02-20 | Duke University | Inhibiting GS-FDH to modulate NO bioactivity |
JP2002226464A (ja) | 2001-01-30 | 2002-08-14 | Sumitomo Pharmaceut Co Ltd | トリアリール類縁体およびその利用 |
CA2452606C (en) * | 2001-07-02 | 2011-09-13 | Akzo Nobel N.V. | Tetrahydroquinoline derivatives |
CA2454080A1 (en) | 2001-08-13 | 2003-02-27 | Robert Edward Detlefsen | Ultraviolet light absorbers |
AT500490A1 (de) | 2001-10-16 | 2006-01-15 | Dsm Fine Chem Austria Gmbh | Verfahren zur herstellung von substituierten thiazolinen und deren zwischenprodukte |
CA2496633A1 (en) | 2002-08-30 | 2004-04-29 | Bf Research Institute, Inc. | Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein |
EP1574500A1 (en) | 2002-12-16 | 2005-09-14 | BF Research Institute, Inc. | Quinoline derivative as diagnostic probe for disease with tau protein accumulation |
BRPI0408188A (pt) | 2003-03-10 | 2006-04-04 | Basf Ag | uso de derivados benzo (hetero) cìclicos amino substituìdos, e, métodos para o controle de insetos, aracnìdeos ou nematódeos, e para a proteção de plantas em crescimento contra o ataque ou infestação por insetos, aracnìdeos ou nematódeos |
CL2004000985A1 (es) | 2003-05-16 | 2005-01-14 | Wyeth Corp | Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc |
JP2007525952A (ja) | 2003-06-04 | 2007-09-13 | デューク・ユニバーシティ | S−ニトロソグルタチオンレダクターゼを調節するための組成物および方法 |
AU2003304416A1 (en) | 2003-08-13 | 2005-03-07 | Bf Research Institute, Inc. | Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change |
CA2551552A1 (en) | 2003-12-23 | 2005-07-14 | Myogen, Inc. | 5-ht2 receptors modulators, their pharmaceuticals compositions and their use for the treatment of cardiovascular and muscle diseases |
ITTO20040125A1 (it) | 2004-03-01 | 2004-06-01 | Rotta Research Lab | Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica |
WO2005118580A2 (en) | 2004-05-12 | 2005-12-15 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health | Tricyclic compounds as inhibitors of the hypoxic signaling pathway |
US20060014705A1 (en) | 2004-06-30 | 2006-01-19 | Howitz Konrad T | Compositions and methods for selectively activating human sirtuins |
WO2006034512A2 (en) * | 2004-09-23 | 2006-03-30 | Bayer Pharmaceuticals Corporation | Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes |
SE0402925D0 (sv) * | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
EP1819342A4 (en) * | 2004-12-03 | 2008-12-17 | Merck & Co Inc | QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS |
EP1683523A1 (en) | 2005-01-25 | 2006-07-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | 2-Phenylquinoxalines as inhibitors for MPP1 |
EP1891039A1 (en) | 2005-05-20 | 2008-02-27 | Vertex Pharmaceuticals Incorporated | Quinoline derivatives useful as modulators of ion channels |
EP3312292B1 (en) * | 2005-05-31 | 2019-09-25 | Promega Corporation | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions |
JP2009500347A (ja) | 2005-06-30 | 2009-01-08 | アムジエン・インコーポレーテツド | ビスアリールキナーゼ阻害剤及びこれらの炎症、血管新生及び癌の治療における使用 |
EP2314295B1 (en) * | 2005-07-29 | 2015-01-28 | Resverlogix, Inc | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
GB0618168D0 (en) | 2006-09-15 | 2006-10-25 | Babraham Inst | Compounds |
KR101299233B1 (ko) | 2006-10-31 | 2013-08-22 | 삼성디스플레이 주식회사 | 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자 |
EP2099458A4 (en) | 2006-12-01 | 2011-05-11 | Harvard College | COMPOUNDS AND METHODS FOR IMAGING AND THERAPY OF ENZYME-MEDIATED TUMORS |
WO2009008906A2 (en) | 2007-02-06 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Therapeutic compounds for blocking dna synthesis of pox viruses |
DE102007015169A1 (de) * | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
BRPI0701664A2 (pt) | 2007-05-28 | 2009-01-13 | Fundacao Universidade Fed De Sco Carlos | 4-quinolinonas e quinolinas, processo de preparaÇço, formulaÇÕes farmacÊuticas e uso das mesmas |
WO2008157500A1 (en) | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
EP2014651A1 (en) | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Compounds and methods for modulating Rho GTPases |
EP2581451B1 (en) | 2007-12-13 | 2016-03-09 | Indiana University Research and Technology Corporation | Compounds for inhibiting mammalian s-nitrosoglutathione reductase |
US20100144733A1 (en) | 2008-04-28 | 2010-06-10 | Institute For Oneworld Health | Compounds, compositions and methods comprising heteroaromatic derivatives |
KR101696936B1 (ko) * | 2008-07-10 | 2017-01-16 | 잇반샤단호우징 화루마바레프로제쿠토 시엥기코우 | 퀴놀린카르복사미드 유도체를 유효 성분으로 하는 stat3 저해제 |
WO2010018458A2 (en) | 2008-08-12 | 2010-02-18 | Crystalgenomics, Inc. | Phenol derivatives and methods of use thereof |
EP2315590B1 (en) * | 2008-08-15 | 2012-09-26 | N30 Pharmaceuticals, LLC | Pyrrole inhibitors of s-nitrosoglutathione reductase |
US8470857B2 (en) | 2008-08-15 | 2013-06-25 | N30 Pharmaceuticals, Inc. | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents |
KR20110042364A (ko) * | 2008-08-15 | 2011-04-26 | 엔30 파머수티컬즈 엘엘씨 | 치료제로서 s-니트로소글루타티온 리덕타아제의 신규한 피롤 억제제 |
MX2011004088A (es) * | 2008-10-15 | 2011-09-06 | Kissei Pharmaceutical | Derivado de anillo fusionado y su aplicacion medica. |
US8513282B2 (en) | 2008-10-23 | 2013-08-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2010107476A1 (en) | 2009-03-19 | 2010-09-23 | Duke University | Inhibiting gsnor |
US8722695B2 (en) | 2009-12-11 | 2014-05-13 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
RU2585763C2 (ru) | 2010-02-12 | 2016-06-10 | Нивалис Терапьютикс,Инк. | Новые ингибиторы s-нитрозоглутатионредуктазы |
US8921562B2 (en) * | 2010-10-08 | 2014-12-30 | N30 Pharmaceuticals, Inc. | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors |
CN103328430A (zh) | 2010-12-16 | 2013-09-25 | N30医药品公司 | 作为s-亚硝基谷胱甘肽还原酶抑制剂的新型取代的双环芳族化合物 |
WO2012170371A1 (en) | 2011-06-10 | 2012-12-13 | N30 Pharmaceuticals, Llc | Compounds as s-nitrosoglutathione reductase inhibitors |
-
2011
- 2011-10-07 US US13/824,430 patent/US8921562B2/en active Active
- 2011-10-07 AU AU2011311920A patent/AU2011311920B2/en not_active Ceased
- 2011-10-07 IN IN501MUN2013 patent/IN2013MN00501A/en unknown
- 2011-10-07 BR BR112013007907A patent/BR112013007907A2/pt not_active Application Discontinuation
- 2011-10-07 EP EP11831651.2A patent/EP2624695B1/en active Active
- 2011-10-07 JP JP2013532965A patent/JP5855113B2/ja not_active Expired - Fee Related
- 2011-10-07 PT PT118316512T patent/PT2624695E/pt unknown
- 2011-10-07 EP EP15180449.9A patent/EP2977050A1/en not_active Withdrawn
- 2011-10-07 HU HUE11831651A patent/HUE025653T2/hu unknown
- 2011-10-07 PL PL11831651T patent/PL2624695T3/pl unknown
- 2011-10-07 ES ES11831651.2T patent/ES2553771T3/es active Active
- 2011-10-07 CN CN201180052350.7A patent/CN103200820B/zh active Active
- 2011-10-07 RU RU2013112122/04A patent/RU2599144C2/ru active IP Right Revival
- 2011-10-07 WO PCT/US2011/055200 patent/WO2012048181A1/en active Application Filing
- 2011-10-07 SI SI201130672T patent/SI2624695T1/sl unknown
- 2011-10-07 KR KR1020137010664A patent/KR101886459B1/ko active IP Right Grant
- 2011-10-07 RS RS20150786A patent/RS54369B1/en unknown
- 2011-10-07 CA CA2811791A patent/CA2811791C/en active Active
- 2011-10-07 DK DK11831651.2T patent/DK2624695T3/en active
-
2012
- 2012-12-24 IL IL223829A patent/IL223829A/en not_active IP Right Cessation
-
2013
- 2013-05-06 ZA ZA2013/03257A patent/ZA201303257B/en unknown
-
2014
- 2014-01-13 HK HK14100371.3A patent/HK1187207A1/xx not_active IP Right Cessation
- 2014-11-13 US US14/540,216 patent/US9139528B2/en not_active Expired - Fee Related
-
2015
- 2015-08-04 US US14/817,329 patent/US9315462B2/en active Active
- 2015-10-19 JP JP2015205282A patent/JP2016074667A/ja active Pending
- 2015-12-21 HR HRP20151405TT patent/HRP20151405T1/hr unknown
-
2016
- 2016-01-21 SM SM201600021T patent/SMT201600021B/it unknown
- 2016-04-06 HK HK16103862.1A patent/HK1215862A1/zh unknown
- 2016-04-13 US US15/097,378 patent/US9433618B2/en active Active
- 2016-08-04 US US15/228,088 patent/US9856219B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013007907A2 (pt) | novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase | |
CO6920291A2 (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idhmutante | |
CR20130192A (es) | Derivados de bencimidazol como inhibidores de cinasa p13 | |
CO6920292A2 (es) | Compuesto de quinolona | |
CR20120576A (es) | Inhibidores de pirazolil quinazolina cinasa | |
HK1178742A1 (zh) | -亞硝基谷胱甘肽還原酶的新抑制劑 | |
CO7061086A2 (es) | Combinaciones de compuestos activos | |
BR112013010099A2 (pt) | boronatos como inibidores de arginase | |
CO6831983A2 (es) | Compuestos heterocíclicos como inhibidores de cinasas | |
CO6930358A2 (es) | Compuestos inhibidores de metaloenzimas | |
DOP2012000282A (es) | Indoles sustituidos como inhibidores ezh2 | |
CU24109B1 (es) | Compuestos pirimidinílicos como inhibidores de la cinasa atr | |
BR112013003753A2 (pt) | compostos | |
SMT201600328B (it) | Nuovi composti come inibitori di diacilglicerolo aciltransferasi | |
BR112013015449A2 (pt) | compostos de bi-heteroarila como inibidores de vps23 | |
CO6880068A2 (es) | Aminoquinazolinas como inhibidores de quinasa | |
DK2648516T3 (da) | Substituerede pyridinon-pyridinylforbindelser | |
BR112013014681A2 (pt) | novos compostos aromáticos bicíclicos substituídos como inibidores de s-nitrosoglutationa redutase | |
CU24164B1 (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
CO6900144A2 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
BR112012030193A2 (pt) | compostos macrocíclicos úteis como inibidores de histona desacetilases | |
UY33155A (es) | Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa | |
CO7010839A2 (es) | Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2 | |
CO6791617A2 (es) | Combinaciones de compuestos activos | |
BR112013014484A2 (pt) | compostos inibidores de metaloenzimas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: NIVALIS THERAPEUTICS, INC. (US) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |